ReviewFrontiers in immunology2026
Nanomedicine delivery systems remodel the immunosuppressive microenvironment of colorectal cancer: synergistic strategies and mechanisms of targeted immune checkpoint inhibitors.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a highly prevalent malignancy worldwide. Traditional treatments, including surgery, chemotherapy, and radiotherapy, have limited efficacy in advanced-stage patients, therefore innovative strategies are urgently needed. Targeted immunotherapy and nanomedicine, as emerging therapeutic directions, offer new possibilities to address this therapeutic impasse. This review systematically summarizes the current application of targeted immunotherapy (immune checkpoint inhibitors, CAR-T cell therapy, and tumor vaccines) in CRC, as well as the research progress of nanomedicine (e.g., liposomes, polymeric nanoparticles, and metal nanoparticles) in drug delivery, immunomodulation, and combination therapy. By analyzing the latest research findings, this review explores the synergistic mechanisms of these two approaches, the clinical challenges, and future development directions, aiming to provide a theoretical basis and practical guidance for the precision treatment of CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.